Animal models have suggested that the compensatory hyperinsulinemia occurring with PI3K inhibitor-associated hyperglycemia may result in partial reactivation of the PI3K/AKT/mTOR pathway and counter the anti-cancer effectiveness of PI3K inhibitors (8). The gene discussed is MTOR; the disease is cancer.